Identifying Risk Factors For Toxicity In Patients With Hormone-Receptor Positive Advanced Breast Cancer Treated With Bevacizumab Plus Letrozole: A CALGB 40503 (Alliance) Correlative Study
- Citation:
- J Clin Oncol vol 34 (suppl) abstr 10047
- Meeting Instance:
- ASCO 2016
- Year:
- 2016
- Type:
- Abstract
- Sub type:
- Poster General
- Funding:
- NCTN
- Endpoint:
- Secondary
- Analysis:
- Primary
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- epub
- Note:
- Methodological:
- No
- Biospecimen:
- No
- SDC:
- No
- Parents:
- None
- Children:
- 2931
- Program:
- CCP
- Primary Committee:
- Older Adult
- Sec. Committees:
- Breast
- Pharmas:
- Genentech
- Grants:
- UG1CA189823, P30CA033572, U10CA180790, U10CA180795, U10CA180820, U10CA180836, U10CA180838, U10CA180857, U10CA180858, U10CA180867, U10CA180888
- Corr. Author:
- Authors:
- Daneng Li Maura N. Dickler Linda M. McCall Olwen M Hahn Clifford A. Hudis Harvey J. Cohen Hyman B. Muss Karla V. Ballman Eric P. Winer Debu Tripathy Bryan Schneider Constance Cirrincione William Barry Arti Hurria
- Networks:
- CA043, LAPS-CT018, LAPS-IL057, LAPS-NC007, LAPS-NC010, LAPS-NY016, LAPS-TX035, NY018
- Study
- CALGB-40503
- Multiple Studies, or Legacy Studies in Alliance Study:
- Phases:
- 3
- Keywords: